Targeting the CD47–SIRPα axis results in a functional skewing of macrophages toward an M1-like phenotype in tumor models, thus contributing to antitumor immune response, and it has promising clinical prospective in PDAC therapy. The gene discussed is SIRPA; the disease is neoplasm.